ESR1 and breast cancer: The following studies demonstrated that rs3803662 was not only associated with increased risk of breast cancer in both BRCA1 and BRCA2-mutation carriers and estrogen receptor (ER) positive patients [16], male breast cancer [17, 18], triple-negative (TN) breast cancer [19, 20], but also with overall survival (OS) of breast cancer [21, 22].